Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Dany Abi, Gerges"'
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S248
Introduction Discordant lymphoma is the condition in which two subtypes of lymphoma occur synchronously in different anatomical sites. The objective is to highlight this exceptionally rare combination in order to prevent inaccurate diagnosis. Case Pr
Autor:
Siham Fleifel, Rami Nassabein, Dany Abi Gerges, Hussein Farhat, Wassim Serhal, Noha Bejjani, Roland De Wind, Hady Ghanem
Publikováno v:
Journal of Blood & Lymph.
Composite lymphoma is a rare entity of lymphoma where two types of lymphoma are present synchronously. We recently encountered two cases of composite lymphomas that are not rare in the morphology and pathology only, but also rare in the site of invol
Autor:
Zaher K. Otrock, Anas Mugharbel, Marwan Ghosn, Georges Chahine, Joseph Kattan, Ziad Salem, Dany Abi Gerges, Joseph Makdessi, Mohamed A. Kharfan-Dabaja, Charles Sfeir, Ahmad Ibrahim, Georges Aftimos, Hussein Sadek, F. Nasr, Mirna El Hajj, Ayman Tawil, Khaled Ibrahim, Hassan Sidani, Michel Saade, Walid Mokaddem, Saad Khairallah, Rami Mahfouz, Zarouhie Meguerian, Claude Ghorra, Christina Khater, Ali Bazarbachi, Walid Dayeh, Fadi Farhat, Ghazi Zaatari, Gerard Abadjian, Jad Saab, Nizar Bitar
Publikováno v:
Pathology & Oncology Research. 19:715-722
Incidence of various Hodgkin (HL) and non-Hodgkin lymphoma (NHL) subtypes and association with viruses in Lebanon are not known. We undertook a nationwide study of 272 patients diagnosed with lymphoma in 2007. HL comprised 32.7 % (n = 89) of cases wh
Autor:
A. Tomova, Constanta Timcheva, Dany Abi Gerges, Stanislav Spanik, Thomas Brodowicz, Rupert Bartsch, Christoph C. Zielinski, Moshe Inbar, Christoph Wiltschke, Jan Pawlega, Valentina Tzekova
Publikováno v:
Breast Cancer Research and Treatment. 119:169-176
Docetaxel (D) plus gemcitabine (G) is an active combination in anthracycline pre-treated breast cancer. Impact of sequential administration of these drugs is unclear. This trial aimed to compare concomitant DG with sequential D → G. Patients were r
Autor:
Manuel Ramos-Vázquez, Alexey Manikhas, Nicole McCarthy, John R. Mackey, Dmitriy Krasnozhon, Francois Thireau, Oleg Lipatov, H Fung, A. Ibrahim, Miguel Martin, Karen A. Gelmon, Marc Buyse, Lorinda Simms, Roberto Hegg, Gottfried E. Konecny, Vladimir Semiglazov, Marc Webster, Dany Abi Gerges, Vera Gorbunova, Sunil Verma
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 33, iss 2
Mackey, JR; Ramos-Vazquez, M; Lipatov, O; McCarthy, N; Krasnozhon, D; Semiglazov, V; et al.(2015). Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. Journal of Clinical Oncology, 33(2), 141-148. doi: 10.1200/JCO.2014.57.1513. UCLA: Retrieved from: http://www.escholarship.org/uc/item/0jv62381
Mackey, JR; Ramos-Vazquez, M; Lipatov, O; McCarthy, N; Krasnozhon, D; Semiglazov, V; et al.(2015). Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. Journal of Clinical Oncology, 33(2), 141-148. doi: 10.1200/JCO.2014.57.1513. UCLA: Retrieved from: http://www.escholarship.org/uc/item/0jv62381
Purpose Currently, antiangiogenic strategies in metastatic breast cancer have demonstrated modest improvements in progression-free survival (PFS) but not improved quality or duration of survival, warranting evaluation of new agents in a placebo-contr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6477b1548fc6344b36e773cda00530b0
https://escholarship.org/uc/item/0jv62381
https://escholarship.org/uc/item/0jv62381
Autor:
Ali Shamseddine, George Y. Chahine, Chadi Saba, Fadi Nasr, Bassim Kobrossy, W. Moukadem, Joseph Kattan, Dany Abi Gerges, Sarah Abdel Massih, Fadi Farhat
Publikováno v:
Annals of Oncology. 28:iii106
Autor:
Georges Aftimos, Dany Abi Gerges, W. Salamoun, Saad Khairallah, C.H.Abou Sleiman, Edouard Elias, Joseph Abou Atmeh, Henri Azar, Nuha Bejjani, Georges El Hajj, Nada Moukharbel
Publikováno v:
Molecular immunology. 39(17-18)
Autor:
Zaher K. Otrock, Georges Aftimos, Walid Dayeh, Michel Saade, Saad Khairallah, Rami Mahfouz, Claude Ghorra, Ghazi Zaatari, Christina Khater, J. Kattan, Ali Bazarbachi, Ahmad Ibrahim, Joseph Makdessi, Nizar Bitar, Mohamed A. Kharfan-Dabaja, Anas Mugharbel, Mirna El Hajj, Fadi Farhat, Fadi Nasr, Charles Sfeir, Hussein Sadek, Walid Mokaddem, Hassan Sidani, Marwan Ghosn, Gerard Abadjian, Jad Saab, Georges Chahine, Dany Abi Gerges, Khaled Ibrahim, Ayman Tawil, Ziad Salem, Zarouhie Meguerian
Publikováno v:
Blood. 118:5220-5220
Abstract 5220 Background: lymphoid neoplasms represent a diverse group of neoplasms that are broadly classified into non-Hodgkin lymphomas (NHL) and Hodgkin lymphoma (HL). Incidence of particular subtypes and pathogenic associations with certain vira